Works matching AU Ahn, Myung-Ju

Results: 148
    1
    2
    3
    4
    5

    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC).

    Published in:
    Clinical Lung Cancer, 2021, v. 22, n. 4, p. 301, doi. 10.1016/j.cllc.2021.02.010
    By:
    • Garon, Edward B.;
    • Cho, Byoung Chul;
    • Reinmuth, Niels;
    • Lee, Ki Hyeong;
    • Luft, Alexander;
    • Ahn, Myung-Ju;
    • Robinet, Gilles;
    • Le Moulec, Sylvestre;
    • Natale, Ronald;
    • Schneider, Jeffrey;
    • Shepherd, Frances A.;
    • Garassino, Marina Chiara;
    • Geater, Sarayut Lucien;
    • Szekely, Zsolt Papai;
    • Van Ngoc, Tran;
    • Liu, Feng;
    • Scheuring, Urban;
    • Patel, Nikunj;
    • Peters, Solange;
    • Rizvi, Naiyer A.
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13

    A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    Published in:
    Targeted Oncology, 2023, v. 18, n. 6, p. 853, doi. 10.1007/s11523-023-00997-z
    By:
    • Razak, Albiruni R. Abdul;
    • Wang, Hung-Ming;
    • Chang, Jang-Yang;
    • Ahn, Myung-Ju;
    • Munster, Pamela;
    • Blumenschein Jr, George;
    • Solomon, Benjamin;
    • Lim, Darren Wan-Teck;
    • Hong, Ruey-Long;
    • Pfister, David;
    • Saba, Nabil F.;
    • Lee, Se-Hoon;
    • van Herpen, Carla;
    • Quadt, Cornelia;
    • Bootle, Douglas;
    • Blumenstein, Lars;
    • Demanse, David;
    • Delord, Jean-Pierre
    Publication type:
    Article
    14
    15

    Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 8, p. 2459, doi. 10.1007/s00432-021-03527-4
    By:
    • Park, Ji Hyun;
    • You, Gun Lyung;
    • Ahn, Myung-Ju;
    • Kim, Sang-We;
    • Hong, Min Hee;
    • Han, Ji-Youn;
    • Ock, Chan-Young;
    • Lee, Jong-Seok;
    • Oh, In Jae;
    • Lee, Shin Yup;
    • Kim, Cheol Hyeon;
    • Min, Young Joo;
    • Choi, Yoon Hee;
    • Ryu, Jeong-Seon;
    • Park, Sun Hyo;
    • Ahn, Hee Kyung;
    • Shim, Byoung-Yong;
    • Lee, Ki Hyeong;
    • Lee, Sung Yong;
    • Kim, Jin-Soo
    Publication type:
    Article
    16
    17

    Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 12, p. 3359, doi. 10.1007/s00432-020-03316-5
    By:
    • Park, Ji Hyun;
    • Chun, Sang Hoon;
    • Lee, Yun-Gyoo;
    • Chang, Hyun;
    • Lee, Keun-Wook;
    • Kim, Hye Ryun;
    • Shin, Seong Hoon;
    • An, Ho Jung;
    • Lee, Kyoung Eun;
    • Hwang, In Gyu;
    • Ahn, Myung-Ju;
    • Kim, Sung-Bae;
    • Keam, Bhumsuk
    Publication type:
    Article
    18
    19
    20
    21

    Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w
    By:
    • Kim, Hye In;
    • Kim, Won Gu;
    • Kim, Mijin;
    • Ko, Nak Gyeong;
    • Jin, Mihyeon;
    • Jung, Hyun Ae;
    • Sun, Jong-Mu;
    • Ahn, Jin Seok;
    • Ahn, Myung-Ju;
    • Choi, Yoon-La;
    • Jeon, Min Ji;
    • Kim, Tae Yong;
    • Kim, Won Bae;
    • Kim, Sang-We;
    • Lee, Dae Ho;
    • Jang, Se Jin;
    • Kim, Sun Wook;
    • Chung, Jae Hoon;
    • Kim, Tae Hyuk;
    • Lee, Se-Hoon
    Publication type:
    Article
    22

    Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03852-w
    By:
    • Kim, Hye In;
    • Kim, Won Gu;
    • Kim, Mijin;
    • Ko, Nak Gyeong;
    • Jin, Mihyeon;
    • Jung, Hyun Ae;
    • Sun, Jong-Mu;
    • Ahn, Jin Seok;
    • Ahn, Myung-Ju;
    • Choi, Yoon-La;
    • Jeon, Min Ji;
    • Kim, Tae Yong;
    • Kim, Won Bae;
    • Kim, Sang-We;
    • Lee, Dae Ho;
    • Jang, Se Jin;
    • Kim, Sun Wook;
    • Chung, Jae Hoon;
    • Kim, Tae Hyuk;
    • Lee, Se-Hoon
    Publication type:
    Article
    23

    Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

    Published in:
    Cancer Immunology, Immunotherapy, 2024, v. 73, n. 4, p. 1, doi. 10.1007/s00262-024-03643-3
    By:
    • Seiwert, Tanguy Y.;
    • Wildsmith, Sophie;
    • Fayette, Jérôme;
    • Harrington, Kevin;
    • Gillison, Maura;
    • Ahn, Myung-Ju;
    • Takahashi, Shunji;
    • Weiss, Jared;
    • Machiels, Jean-Pascal;
    • Baxi, Shrujal;
    • Baker, Valerie;
    • Evans, Brent;
    • Morsli, Nassim;
    • Jill Walker;
    • Real, Katia;
    • L'Hernault, Anne;
    • Psyrri, Amanda
    Publication type:
    Article
    24

    Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 5, p. 532, doi. 10.1002/cpdd.427
    By:
    • Tan, Eng‐Huat;
    • Lim, Wan‐Teck;
    • Ahn, Myung‐Ju;
    • Ng, Quan‐Sing;
    • Ahn, Jin Seok;
    • Shao‐Weng Tan, Daniel;
    • Sun, Jong‐Mu;
    • Han, May;
    • Payumo, Francis C.;
    • McKee, Krista;
    • Yin, Wei;
    • Credi, Marc;
    • Agarwal, Shefali;
    • Jac, Jaroslaw;
    • Park, Keunchil
    Publication type:
    Article
    25
    26
    27
    28

    Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).

    Published in:
    2017
    By:
    • Kim, Youjin;
    • Lee, Su Jin;
    • Lee, Ji Yun;
    • Lee, Se‐Hoon;
    • Sun, Jong‐Mu;
    • Park, Keunchil;
    • An, Ho Jung;
    • Cho, Jae Yong;
    • Kang, Eun Joo;
    • Lee, Ha‐Young;
    • Kim, Jinsoo;
    • Keam, Bhumsuk;
    • Kim, Hye Ryun;
    • Lee, Kyoung Eun;
    • Choi, Moon Young;
    • Lee, Ki Hyeong;
    • Ahn, Myung‐Ju;
    • Lee, Se-Hoon;
    • Sun, Jong-Mu;
    • Lee, Ha-Young
    Publication type:
    journal article
    29
    30

    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).

    Published in:
    Cancer (0008543X), 2012, v. 118, n. 24, p. 6234, doi. 10.1002/cncr.27630
    By:
    • Sun, Jong-Mu;
    • Lee, Ki Hyeong;
    • Kim, Sang-we;
    • Lee, Dae Ho;
    • Min, Young Joo;
    • Yun, Hwan Jung;
    • Kim, Hoon Kyo;
    • Song, Hong Suk;
    • Kim, Yeul Hong;
    • Kim, Bong-Seog;
    • Hwang, In Gyu;
    • Lee, Keehyun;
    • Jo, Sook Jung;
    • Lee, Jae Won;
    • Ahn, Jin Seok;
    • Park, Keunchil;
    • Ahn, Myung-Ju
    Publication type:
    Article
    31

    Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.

    Published in:
    BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03620-8
    By:
    • Han, Ji-Youn;
    • Ahn, Myung-Ju;
    • Lee, Ki Hyeong;
    • Lee, Yun-Gyoo;
    • Kim, Dong-Wan;
    • Min, Young Joo;
    • Kim, Sang-We;
    • Cho, Eun Kyung;
    • Kim, Joo-Hang;
    • Lee, Gyeong-Won;
    • Lee, Sung Sook;
    • Lee, Na Mi;
    • Jang, Hyun Woo;
    • Han, Heewon;
    • Park, Hyejoo;
    • Lee, Jieon;
    • Cho, Byoung Chul
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.

    Published in:
    Scientific Reports, 2016, p. 19552, doi. 10.1038/srep19552
    By:
    • Huang, Kie Kyon;
    • Jang, Kang Won;
    • Kim, Sangwoo;
    • Kim, Han Sang;
    • Kim, Sung-Moo;
    • Kwon, Hyeong Ju;
    • Kim, Hye Ryun;
    • Yun, Hwan Jung;
    • Ahn, Myung Ju;
    • Park, Keon Uk;
    • Ramnarayanan, Kalpana;
    • McPherson, John R.;
    • Zhang, Shenli;
    • Rhee, Je-Keun;
    • Vettore, André L.;
    • Das, Kakoli;
    • Ishimoto, Takatsugu;
    • Kim, Joo Hang;
    • Koh, Yoon Woo;
    • Kim, Se Hun
    Publication type:
    Article